1/4/2013

Pfizer secured exclusive, worldwide rights to develop and market Philogen's Dekavil, an investigational drug for autoimmune diseases. Dekavil is an early-stage antibody that targets inflammatory disease sites. The deal entitles Philogen to an an upfront fee and potential milestone fees and royalties.

Full Story:
Reuters

Related Summaries